Skip to content
DataLookout
Menu

NCT04500665

Anti-Inflammatory Treatment of Uremic Cardiomyopathy With Colchicine

StatusTerminated
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 10 versions: 9 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Stopped Trial terminated Sponsor's reason: Funding Show 4 more changesShow less
    • Eligibility criteria expanded, about 30 words
    • Final enrollment: 4 participants (planned 20)
    • Primary completion date changed from estimate of Jul 31, 2026 to Nov 13, 2026
    • Site details revised
  2. Notable Primary completion date: Dec 31, 2025 to Jul 31, 2026v9
  3. Notable Eligibility criteria shortened, about 3 wordsv8
  4. Notable Primary completion date: Dec 31, 2024 to Dec 31, 2025
    • Eligibility criteria shortened, about 74 words
    • Study completion date: Nov 11, 2025 to Nov 11, 2026
    v7
  5. Notable Eligibility criteria shortened, about 50 wordsv5
Show 3 earlier versionsHide 3 earlier versions
  1. Notable Trial status: Not Yet Recruiting to Recruiting
    • Eligibility criteria expanded, about 101 words
    • Start date changed from estimate of Sep 2021 to Nov 1, 2021
    • Site details revised
    v4
  2. Notable Start date: Feb 1, 2021 to Sep 2021
    • Study sites: 0 to 1
    v3
  3. Notable Start date: Oct 1, 2020 to Feb 1, 2021v2
  1. Study First Submitted
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed

Endpoints

Primary

Between-group change in left ventricular global longitudinal strain
Timeframe: 4 weeks

Secondary (4)

Between-group change in left ventricular systolic and diastolic function
Between-group change in left ventricular volumes
Between-group change in left ventricular size
Between-group change in systemic inflammation

Arms and interventions

ColchicineExperimental

Colchicine 0.3 mg once daily

PlaceboPlacebo comparator

Placebo once daily

Drugs: Colchicine, Placebo

Sites

1 site in 1 country

  • Brigham and Women's HospitalBoston, Massachusetts, United States